Blake Kathryn, Lima John
Biomedical Research Department, Center for Clinical Pharmacogenomics and Translational Research, Nemours Children's Clinic, 807 Children's Way, Jacksonville, FL 32207, USA.
Anemia. 2011;2011:740235. doi: 10.1155/2011/740235. Epub 2011 Mar 3.
Objective. To review issues related to asthma in sickle cell disease and management strategies. Data Source. A systematic review of pertinent original research publications, reviews, and editorials was undertaken using MEDLlNE, the Cochrane Library databases, and CINAHL from 1947 to November 2010. Search terms were [asthma] and [sickle cell disease]. Additional publications considered relevant to the sickle cell disease population of patients were identified; search terms included [sickle cell disease] combined with [acetaminophen], [pain medications], [vitamin D], [beta agonists], [exhaled nitric oxide], and [corticosteroids]. Results. The reported prevalence of asthma in children with sickle cell disease varies from 2% to approximately 50%. Having asthma increases the risk for developing acute chest syndrome , death, or painful episodes compared to having sickle cell disease without asthma. Asthma and sickle cell may be linked by impaired nitric oxide regulation, excessive production of leukotrienes, insufficient levels of Vitamin D, and exposure to acetaminophen in early life. Treatment of sickle cell patients includes using commonly prescribed asthma medications; specific considerations are suggested to ensure safety in the sickle cell population. Conclusion. Prospective controlled trials of drug treatment for asthma in patients who have both sickle cell disease and asthma are urgently needed.
目的。回顾镰状细胞病中与哮喘相关的问题及管理策略。数据来源。使用MEDLINE、Cochrane图书馆数据库和CINAHL对1947年至2010年11月的相关原始研究出版物、综述和社论进行系统回顾。检索词为[哮喘]和[镰状细胞病]。确定了其他与镰状细胞病患者群体相关的出版物;检索词包括[镰状细胞病]与[对乙酰氨基酚]、[止痛药]、[维生素D]、[β受体激动剂]、[呼出一氧化氮]和[皮质类固醇]的组合。结果。报告的镰状细胞病患儿哮喘患病率从2%到约50%不等。与无哮喘的镰状细胞病患者相比,患哮喘会增加发生急性胸综合征、死亡或疼痛发作的风险。哮喘和镰状细胞病可能通过一氧化氮调节受损、白三烯产生过多、维生素D水平不足以及早年接触对乙酰氨基酚而相互关联。镰状细胞病患者的治疗包括使用常用的哮喘药物;建议特别考虑以确保镰状细胞病患者群体的安全。结论。迫切需要对同时患有镰状细胞病和哮喘的患者进行哮喘药物治疗的前瞻性对照试验。